BRCA1 and BRCA2 deficient tumour models generate distinct ovarian tumour microenvironments and differential responses to therapy

Clinical trials are currently exploring combinations of PARP inhibitors and immunotherapies for the treatment of ovarian cancer, but their effects on the ovarian tumour microenvironment (TME) remain unclear. Here, we investigate how olaparib, PD-L1 monoclonal antibodies, and their combination can in...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Journal of ovarian research Ročník 16; číslo 1; s. 231 - 16
Hlavní autoři:	Farokhi Boroujeni, Salar, Rodriguez, Galaxia, Galpin, Kristianne, Yakubovich, Edward, Murshed, Humaira, Ibrahim, Dalia, Asif, Sara, Vanderhyden, Barbara C.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	London BioMed Central 28.11.2023 BioMed Central Ltd Springer Nature B.V BMC
Témata:	Analysis Angiogenesis Animals B7-H1 Antigen - genetics BRCA mutations BRCA1 protein BRCA1 Protein - genetics BRCA2 protein BRCA2 Protein - genetics Breast cancer Cancer Cancer therapies Care and treatment Cell death Clinical trials DNA damage DNA repair Female Genes, BRCA2 Genomes Gynecology Humans Immune checkpoint inhibitors Immunomodulation Immunotherapy Inflammation Medical prognosis Medicine Medicine & Public Health Mice Monoclonal antibodies Mutation Ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - genetics Ovarian Neoplasms - metabolism PARP inhibitors PD-L1 protein Poly(ADP-ribose) Polymerase Inhibitors - pharmacology Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use Reproductive Medicine RNA Survival Tumor microenvironment Tumor Microenvironment - genetics Tumors Immune checkpoint inhibitors mutations PARP inhibitors Ovarian cancer BRCA mutations
ISSN:	1757-2215, 1757-2215
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	Clinical trials are currently exploring combinations of PARP inhibitors and immunotherapies for the treatment of ovarian cancer, but their effects on the ovarian tumour microenvironment (TME) remain unclear. Here, we investigate how olaparib, PD-L1 monoclonal antibodies, and their combination can influence TME composition and survival of tumour-bearing mice. We further explored how BRCA deficiencies can influence the response to therapy. Olaparib and combination therapies similarly improved the median survival of Brca1 - and Brca2 -deficient tumour-bearing mice. Anti-PD-L1 monotherapy improved the survival of mice with Brca1- null tumours, but not Brca2- null tumours. A detailed analysis of the TME revealed that olaparib monotherapy resulted in a large number of immunosuppressive and immunomodulatory effects in the more inflamed Brca1- deficient TME but not Brca2- deficient tumours. Anti-PD-L1 treatment was mostly immunosuppressive, resulting in a systemic reduction of cytokines and a compensatory increase in PD-L1 expression. The results of the combination therapy generally resembled the effects of one or both of the monotherapies, along with unique changes observed in certain immune populations. In-silico analysis of RNA-seq data also revealed numerous differences between Brca- deficient tumour models, such as the expression of genes involved in inflammation, angiogenesis and PD-L1 expression. In summary, these findings shed light on the influence of novel therapeutics and BRCA mutations on the ovarian TME.
AbstractList	Clinical trials are currently exploring combinations of PARP inhibitors and immunotherapies for the treatment of ovarian cancer, but their effects on the ovarian tumour microenvironment (TME) remain unclear. Here, we investigate how olaparib, PD-L1 monoclonal antibodies, and their combination can influence TME composition and survival of tumour-bearing mice. We further explored how BRCA deficiencies can influence the response to therapy. Olaparib and combination therapies similarly improved the median survival of Brca1- and Brca2-deficient tumour-bearing mice. Anti-PD-L1 monotherapy improved the survival of mice with Brca1-null tumours, but not Brca2-null tumours. A detailed analysis of the TME revealed that olaparib monotherapy resulted in a large number of immunosuppressive and immunomodulatory effects in the more inflamed Brca1-deficient TME but not Brca2-deficient tumours. Anti-PD-L1 treatment was mostly immunosuppressive, resulting in a systemic reduction of cytokines and a compensatory increase in PD-L1 expression. The results of the combination therapy generally resembled the effects of one or both of the monotherapies, along with unique changes observed in certain immune populations. In-silico analysis of RNA-seq data also revealed numerous differences between Brca-deficient tumour models, such as the expression of genes involved in inflammation, angiogenesis and PD-L1 expression. In summary, these findings shed light on the influence of novel therapeutics and BRCA mutations on the ovarian TME. Clinical trials are currently exploring combinations of PARP inhibitors and immunotherapies for the treatment of ovarian cancer, but their effects on the ovarian tumour microenvironment (TME) remain unclear. Here, we investigate how olaparib, PD-L1 monoclonal antibodies, and their combination can influence TME composition and survival of tumour-bearing mice. We further explored how BRCA deficiencies can influence the response to therapy. Olaparib and combination therapies similarly improved the median survival of Brca1- and Brca2-deficient tumour-bearing mice. Anti-PD-L1 monotherapy improved the survival of mice with Brca1-null tumours, but not Brca2-null tumours. A detailed analysis of the TME revealed that olaparib monotherapy resulted in a large number of immunosuppressive and immunomodulatory effects in the more inflamed Brca1-deficient TME but not Brca2-deficient tumours. Anti-PD-L1 treatment was mostly immunosuppressive, resulting in a systemic reduction of cytokines and a compensatory increase in PD-L1 expression. The results of the combination therapy generally resembled the effects of one or both of the monotherapies, along with unique changes observed in certain immune populations. In-silico analysis of RNA-seq data also revealed numerous differences between Brca-deficient tumour models, such as the expression of genes involved in inflammation, angiogenesis and PD-L1 expression. In summary, these findings shed light on the influence of novel therapeutics and BRCA mutations on the ovarian TME. Keywords: BRCA mutations, Ovarian cancer, PARP inhibitors, Immune checkpoint inhibitors Abstract Clinical trials are currently exploring combinations of PARP inhibitors and immunotherapies for the treatment of ovarian cancer, but their effects on the ovarian tumour microenvironment (TME) remain unclear. Here, we investigate how olaparib, PD-L1 monoclonal antibodies, and their combination can influence TME composition and survival of tumour-bearing mice. We further explored how BRCA deficiencies can influence the response to therapy. Olaparib and combination therapies similarly improved the median survival of Brca1- and Brca2-deficient tumour-bearing mice. Anti-PD-L1 monotherapy improved the survival of mice with Brca1-null tumours, but not Brca2-null tumours. A detailed analysis of the TME revealed that olaparib monotherapy resulted in a large number of immunosuppressive and immunomodulatory effects in the more inflamed Brca1-deficient TME but not Brca2-deficient tumours. Anti-PD-L1 treatment was mostly immunosuppressive, resulting in a systemic reduction of cytokines and a compensatory increase in PD-L1 expression. The results of the combination therapy generally resembled the effects of one or both of the monotherapies, along with unique changes observed in certain immune populations. In-silico analysis of RNA-seq data also revealed numerous differences between Brca-deficient tumour models, such as the expression of genes involved in inflammation, angiogenesis and PD-L1 expression. In summary, these findings shed light on the influence of novel therapeutics and BRCA mutations on the ovarian TME. Clinical trials are currently exploring combinations of PARP inhibitors and immunotherapies for the treatment of ovarian cancer, but their effects on the ovarian tumour microenvironment (TME) remain unclear. Here, we investigate how olaparib, PD-L1 monoclonal antibodies, and their combination can influence TME composition and survival of tumour-bearing mice. We further explored how BRCA deficiencies can influence the response to therapy. Olaparib and combination therapies similarly improved the median survival of Brca1 - and Brca2 -deficient tumour-bearing mice. Anti-PD-L1 monotherapy improved the survival of mice with Brca1- null tumours, but not Brca2- null tumours. A detailed analysis of the TME revealed that olaparib monotherapy resulted in a large number of immunosuppressive and immunomodulatory effects in the more inflamed Brca1- deficient TME but not Brca2- deficient tumours. Anti-PD-L1 treatment was mostly immunosuppressive, resulting in a systemic reduction of cytokines and a compensatory increase in PD-L1 expression. The results of the combination therapy generally resembled the effects of one or both of the monotherapies, along with unique changes observed in certain immune populations. In-silico analysis of RNA-seq data also revealed numerous differences between Brca- deficient tumour models, such as the expression of genes involved in inflammation, angiogenesis and PD-L1 expression. In summary, these findings shed light on the influence of novel therapeutics and BRCA mutations on the ovarian TME. Clinical trials are currently exploring combinations of PARP inhibitors and immunotherapies for the treatment of ovarian cancer, but their effects on the ovarian tumour microenvironment (TME) remain unclear. Here, we investigate how olaparib, PD-L1 monoclonal antibodies, and their combination can influence TME composition and survival of tumour-bearing mice. We further explored how BRCA deficiencies can influence the response to therapy. Olaparib and combination therapies similarly improved the median survival of Brca1- and Brca2-deficient tumour-bearing mice. Anti-PD-L1 monotherapy improved the survival of mice with Brca1-null tumours, but not Brca2-null tumours. A detailed analysis of the TME revealed that olaparib monotherapy resulted in a large number of immunosuppressive and immunomodulatory effects in the more inflamed Brca1-deficient TME but not Brca2-deficient tumours. Anti-PD-L1 treatment was mostly immunosuppressive, resulting in a systemic reduction of cytokines and a compensatory increase in PD-L1 expression. The results of the combination therapy generally resembled the effects of one or both of the monotherapies, along with unique changes observed in certain immune populations. In-silico analysis of RNA-seq data also revealed numerous differences between Brca-deficient tumour models, such as the expression of genes involved in inflammation, angiogenesis and PD-L1 expression. In summary, these findings shed light on the influence of novel therapeutics and BRCA mutations on the ovarian TME.Clinical trials are currently exploring combinations of PARP inhibitors and immunotherapies for the treatment of ovarian cancer, but their effects on the ovarian tumour microenvironment (TME) remain unclear. Here, we investigate how olaparib, PD-L1 monoclonal antibodies, and their combination can influence TME composition and survival of tumour-bearing mice. We further explored how BRCA deficiencies can influence the response to therapy. Olaparib and combination therapies similarly improved the median survival of Brca1- and Brca2-deficient tumour-bearing mice. Anti-PD-L1 monotherapy improved the survival of mice with Brca1-null tumours, but not Brca2-null tumours. A detailed analysis of the TME revealed that olaparib monotherapy resulted in a large number of immunosuppressive and immunomodulatory effects in the more inflamed Brca1-deficient TME but not Brca2-deficient tumours. Anti-PD-L1 treatment was mostly immunosuppressive, resulting in a systemic reduction of cytokines and a compensatory increase in PD-L1 expression. The results of the combination therapy generally resembled the effects of one or both of the monotherapies, along with unique changes observed in certain immune populations. In-silico analysis of RNA-seq data also revealed numerous differences between Brca-deficient tumour models, such as the expression of genes involved in inflammation, angiogenesis and PD-L1 expression. In summary, these findings shed light on the influence of novel therapeutics and BRCA mutations on the ovarian TME.
ArticleNumber	231
Audience	Academic
Author	Ibrahim, Dalia Farokhi Boroujeni, Salar Yakubovich, Edward Vanderhyden, Barbara C. Rodriguez, Galaxia Asif, Sara Galpin, Kristianne Murshed, Humaira
Author_xml	– sequence: 1 givenname: Salar surname: Farokhi Boroujeni fullname: Farokhi Boroujeni, Salar organization: Cancer Therapeutics Program, Ottawa Hospital Research Institute, Department of Cellular and Molecular Medicine, University of Ottawa – sequence: 2 givenname: Galaxia surname: Rodriguez fullname: Rodriguez, Galaxia organization: Cancer Therapeutics Program, Ottawa Hospital Research Institute, Department of Cellular and Molecular Medicine, University of Ottawa – sequence: 3 givenname: Kristianne surname: Galpin fullname: Galpin, Kristianne organization: Cancer Therapeutics Program, Ottawa Hospital Research Institute, Department of Cellular and Molecular Medicine, University of Ottawa – sequence: 4 givenname: Edward surname: Yakubovich fullname: Yakubovich, Edward organization: Cancer Therapeutics Program, Ottawa Hospital Research Institute, Department of Cellular and Molecular Medicine, University of Ottawa – sequence: 5 givenname: Humaira surname: Murshed fullname: Murshed, Humaira organization: Cancer Therapeutics Program, Ottawa Hospital Research Institute, Department of Cellular and Molecular Medicine, University of Ottawa – sequence: 6 givenname: Dalia surname: Ibrahim fullname: Ibrahim, Dalia organization: Cancer Therapeutics Program, Ottawa Hospital Research Institute, Department of Cellular and Molecular Medicine, University of Ottawa – sequence: 7 givenname: Sara surname: Asif fullname: Asif, Sara organization: Cancer Therapeutics Program, Ottawa Hospital Research Institute, Department of Biochemistry, Microbiology and Immunology, University of Ottawa – sequence: 8 givenname: Barbara C. surname: Vanderhyden fullname: Vanderhyden, Barbara C. email: bvanderhyden@ohri.ca organization: Cancer Therapeutics Program, Ottawa Hospital Research Institute, Department of Cellular and Molecular Medicine, University of Ottawa
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/38017453$$D View this record in MEDLINE/PubMed
BookMark	eNp9kktr3DAUhU1JaR7tH-iiGAqlG6d6WLJmVSahj0CgUNq10EhXMwoeaSppAsmqP713MnlNKMELy_I5n61zz2GzF1OEpnlLyTGlSn4qlJNedYTxjlBOeXf9ojmggxg6xqjYe7Tebw5LuSBEMtXzV80-V4QOveAHzd-Tn6dT2pro2s2KtQ58sAFibet6mda5XSYHY2nnECGbCq0LpYZoa5suTQ4m3uuCzQniZcgpLtFfbqAueA8ZH4MZ2wxllWKB0tbU1gXyVlevm5fejAXe3N6Pmt9fv_w6_d6d__h2djo976zkk9oxCUpZKRRnwgyGu0FwPzO-59JzIH4ijORKgB9cL4WcOeYkkVZ547kQhvCj5mzLdclc6FUOS5OvdDJB32ykPNcm12BH0NAP0oG1Fkm9nynV9xQY94ZRLz31yPq8Za3WsyU4i8fLZtyB7r6JYaHn6VJTIvEAaoKEj7eEnP6soVS9DMXCOJoIaV00agQTE0o4St8_kV5g3BGz0mxCGA5-oJMH1dzgCUL0CT9sN1A9HXDUREm5YR3_R4WXAxwftssH3N8xfHhkWIAZ66KkcV0DznFX-O5xJPdZ3DUNBWorwJaUksFrG6rZcPAXwojR6E2p9bbUGkutb0qtr9HKnljv6M-a-NZUUBznkB9ie8b1D-EuCew
CitedBy_id	crossref_primary_10_1111_jcmm_70845 crossref_primary_10_1186_s12943_024_02073_0 crossref_primary_10_1007_s10689_024_00431_x
Cites_doi	10.1001/jama.2012.20 10.1038/s41467-023-36211-x 10.1056/NEJMoa020177 10.7717/peerj.10414 10.1038/onc.2017.209 10.1111/jcmm.13678 10.1186/s12967-021-03073-0 10.1371/journal.pone.0007766 10.1371/journal.pone.0215381 10.1186/s13578-021-00724-z 10.20892/j.issn.2095-3941.2016.0084 10.1038/nrc3181 10.1016/j.it.2015.02.008 10.1016/S1470-2045(18)30566-7 10.1126/science.2270482 10.1038/s41598-017-17119-1 10.1371/journal.pone.0080063 10.1158/0008-5472.CAN-21-2076 10.1016/j.ejca.2017.10.030 10.1038/s41580-020-0218-z 10.1016/j.celrep.2021.109412 10.1101/2022.08.31.506095 10.1038/s41590-019-0312-6 10.1158/0008-5472.CAN-16-1272 10.1073/pnas.0509182102 10.1111/cas.14349 10.1038/sj.onc.1205971 10.1038/s42003-023-05529-z 10.1016/j.celrep.2022.110632 10.3389/fimmu.2012.00023 10.1080/2162402X.2018.1424672 10.1200/JCO.2016.68.6907 10.1186/1476-4598-13-244 10.1158/1078-0432.CCR-16-3215 10.1158/2767-9764.CRC-22-0017 10.1038/s41586-022-04421-w 10.1200/JCO.20.00799 10.1056/NEJMoa1810858 10.1080/2162402X.2016.1249561 10.1038/ncomms10501 10.7150/ijbs.8579 10.1101/gad.334433.119 10.1101/cshperspect.a016600 10.4049/jimmunol.178.11.7097 10.1016/j.ygyno.2019.04.078 10.1001/jama.2017.7112
ContentType	Journal Article
Copyright	The Author(s) 2023 2023. The Author(s). COPYRIGHT 2023 BioMed Central Ltd. 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml	– notice: The Author(s) 2023 – notice: 2023. The Author(s). – notice: COPYRIGHT 2023 BioMed Central Ltd. – notice: 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID	C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7T5 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU COVID DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA
DOI	10.1186/s13048-023-01313-z
DatabaseName	Springer_OA刊 CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Immunology Abstracts ProQuest_Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College Coronavirus Research Database ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Open Access Full Text
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition Coronavirus Research Database ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	Publicly Available Content Database CrossRef MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine Anatomy & Physiology
EISSN	1757-2215
EndPage	16
ExternalDocumentID	oai_doaj_org_article_e476deccc4654fb88441e23fa21f6f1f PMC10683289 A774508663 38017453 10_1186_s13048_023_01313_z
Genre	Journal Article
GrantInformation_xml	– fundername: Canadian Institutes of Health Research grantid: CGS-M; CGS-M; CGS-D; PJT-156139 funderid: http://dx.doi.org/10.13039/501100000024 – fundername: CIHR grantid: CGS-D – fundername: CIHR grantid: PJT-156139 – fundername: CIHR grantid: CGS-M – fundername: ; grantid: CGS-M; CGS-M; CGS-D; PJT-156139
GroupedDBID	--- 0R~ 2WC 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML ABDBF ABUWG ACGFS ACPRK ACUHS ADBBV ADRAZ ADUKV AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU DIK E3Z EBD EBLON EBS ESX FYUFA GROUPED_DOAJ GX1 HMCUK IAO ICW IEA IHR IHW INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ ROL RPM RSV SMD SOJ TR2 TUS UKHRP AAYXX AFFHD CITATION -5E -5G -A0 -BR 3V. ACRMQ ADINQ ALIPV C24 CGR CUY CVF ECM EIF NPM 7T5 7XB 8FK AZQEC COVID DWQXO H94 K9. PKEHL PQEST PQUKI PRINS 7X8 5PM
ID	FETCH-LOGICAL-c639t-26e88c658325a7a3d753fbaf436f3e0f95a6385ef7d4656bd2d606c8faf355a03
IEDL.DBID	DOA
ISICitedReferencesCount	7
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001110487300001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1757-2215
IngestDate	Fri Oct 03 12:48:15 EDT 2025 Tue Nov 04 02:06:25 EST 2025 Sun Nov 09 09:38:52 EST 2025 Sat Oct 18 23:49:23 EDT 2025 Tue Nov 11 11:16:53 EST 2025 Tue Nov 04 18:32:08 EST 2025 Thu May 22 21:16:47 EDT 2025 Thu Jan 02 22:41:03 EST 2025 Tue Nov 18 22:14:40 EST 2025 Sat Nov 29 02:06:17 EST 2025 Sat Sep 06 07:29:15 EDT 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	1
Keywords	Immune checkpoint inhibitors mutations PARP inhibitors Ovarian cancer BRCA mutations
Language	English
License	2023. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c639t-26e88c658325a7a3d753fbaf436f3e0f95a6385ef7d4656bd2d606c8faf355a03
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
OpenAccessLink	https://doaj.org/article/e476deccc4654fb88441e23fa21f6f1f
PMID	38017453
PQID	2902131719
PQPubID	54971
PageCount	16
ParticipantIDs	doaj_primary_oai_doaj_org_article_e476deccc4654fb88441e23fa21f6f1f pubmedcentral_primary_oai_pubmedcentral_nih_gov_10683289 proquest_miscellaneous_2895259103 proquest_journals_2902131719 gale_infotracmisc_A774508663 gale_infotracacademiconefile_A774508663 gale_healthsolutions_A774508663 pubmed_primary_38017453 crossref_citationtrail_10_1186_s13048_023_01313_z crossref_primary_10_1186_s13048_023_01313_z springer_journals_10_1186_s13048_023_01313_z
PublicationCentury	2000
PublicationDate	2023-11-28
PublicationDateYYYYMMDD	2023-11-28
PublicationDate_xml	– month: 11 year: 2023 text: 2023-11-28 day: 28
PublicationDecade	2020
PublicationPlace	London
PublicationPlace_xml	– name: London – name: England
PublicationTitle	Journal of ovarian research
PublicationTitleAbbrev	J Ovarian Res
PublicationTitleAlternate	J Ovarian Res
PublicationYear	2023
Publisher	BioMed Central BioMed Central Ltd Springer Nature B.V BMC
Publisher_xml	– name: BioMed Central – name: BioMed Central Ltd – name: Springer Nature B.V – name: BMC
References	S Paul (1313_CR39) 2017; 13 KB Kuchenbaecker (1313_CR17) 2017; 317 M Tarsounas (1313_CR11) 2020; 21 S Lieber (1313_CR32) 2018; 7 J Walton (1313_CR22) 2016; 76 V Kalia (1313_CR33) 2018; 20 Y Kwon (1313_CR10) 2023; 14 K Waki (1313_CR37) 2020; 111 Y Dai (1313_CR43) 2018; 22 CA Penn (1313_CR41) 2019; 154 KE Pauken (1313_CR45) 2015; 36 WX Wen (1313_CR19) 2019; 14 GM Rodriguez (1313_CR54) 2022; 2 CC Preston (1313_CR36) 2013; 8 1313_CR2 R Roy (1313_CR13) 2012; 12 BJG Baaten (1313_CR48) 2012; 3 AA Wright (1313_CR5) 2016; 34 J Meng (1313_CR24) 2021; 19 AVR Kornepati (1313_CR42) 2022; 82 DJ Di (1313_CR53) 2022; 603 DP Cook (1313_CR23) 2023; 6 L Wang (1313_CR47) 2014; 10 S Koyama (1313_CR50) 2016; 7 DS Kim (1313_CR15) 2020; 34 T Bao (1313_CR26) 2021; 11 R Prakash (1313_CR12) 2015; 7 P Disilvestro (1313_CR8) 2020; 38 BC Miller (1313_CR51) 2019; 20 K Bunting (1313_CR25) 2007; 178 H Kawai (1313_CR46) 2002; 21 E Sato (1313_CR30) 2005; 102 JM Hall (1313_CR9) 1990; 250 WX Wen (1313_CR14) 2019; 14 JB Walton (1313_CR21) 2017; 7 S Jiao (1313_CR28) 2017; 23 MR Brett (1313_CR1) 2017; 14 Y Wei (1313_CR20) 2020; 24 Y Liu (1313_CR40) 2017; 36 M Bruand (1313_CR29) 2021; 36 SE Strome (1313_CR44) 2003; 63 I Vergote (1313_CR6) 2018; 19 AU Radziszewska (1313_CR4) 2018; 22 CW Li (1313_CR27) 2016; 30 M Timmermans (1313_CR3) 2018; 88 R Toumi (1313_CR35) 2022; 39 P DiSilvestro (1313_CR16) 2020; 38 L Zhang (1313_CR31) 2003; 348 T Brodbeck (1313_CR38) 2014; 13 KL Bolton (1313_CR18) 2012; 307 YP Lai (1313_CR34) 2009; 4 JJ Hodgins (1313_CR52) 2022; 08 RY Huang (1313_CR49) 2017; 6 K Moore (1313_CR7) 2018; 379
References_xml	– ident: 1313_CR2 – volume: 307 start-page: 382 issue: 4 year: 2012 ident: 1313_CR18 publication-title: JAMA doi: 10.1001/jama.2012.20 – volume: 14 start-page: 432 issue: 1 year: 2023 ident: 1313_CR10 publication-title: Nat Commun doi: 10.1038/s41467-023-36211-x – volume: 348 start-page: 203 issue: 3 year: 2003 ident: 1313_CR31 publication-title: N Engl J Med doi: 10.1056/NEJMoa020177 – volume: 24 start-page: e10414 issue: 8 year: 2020 ident: 1313_CR20 publication-title: PeerJ doi: 10.7717/peerj.10414 – volume: 36 start-page: 6143 issue: 44 year: 2017 ident: 1313_CR40 publication-title: Oncogene doi: 10.1038/onc.2017.209 – volume: 22 start-page: 3979 issue: 8 year: 2018 ident: 1313_CR43 publication-title: J Cell Mol Med doi: 10.1111/jcmm.13678 – volume: 19 start-page: 415 issue: 1 year: 2021 ident: 1313_CR24 publication-title: J Transl Med. doi: 10.1186/s12967-021-03073-0 – volume: 4 start-page: e7766 issue: 11 year: 2009 ident: 1313_CR34 publication-title: PLoS One doi: 10.1371/journal.pone.0007766 – volume: 14 start-page: e0215381 issue: 4 year: 2019 ident: 1313_CR14 publication-title: PLoS ONE doi: 10.1371/journal.pone.0215381 – volume: 11 start-page: 209 issue: 1 year: 2021 ident: 1313_CR26 publication-title: Cell and Bioscience doi: 10.1186/s13578-021-00724-z – volume: 14 start-page: 9 issue: 1 year: 2017 ident: 1313_CR1 publication-title: Cancer Biol Med doi: 10.20892/j.issn.2095-3941.2016.0084 – volume: 12 start-page: 68 issue: 1 year: 2012 ident: 1313_CR13 publication-title: Nat Rev Cancer doi: 10.1038/nrc3181 – volume: 36 start-page: 265 issue: 4 year: 2015 ident: 1313_CR45 publication-title: Trends Immunol doi: 10.1016/j.it.2015.02.008 – volume: 19 start-page: 1680 issue: 12 year: 2018 ident: 1313_CR6 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(18)30566-7 – volume: 250 start-page: 1684 issue: 4988 year: 1990 ident: 1313_CR9 publication-title: Science doi: 10.1126/science.2270482 – volume: 7 start-page: 16827 issue: 1 year: 2017 ident: 1313_CR21 publication-title: Sci Rep doi: 10.1038/s41598-017-17119-1 – volume: 8 start-page: e80063 issue: 11 year: 2013 ident: 1313_CR36 publication-title: PLoS One doi: 10.1371/journal.pone.0080063 – volume: 30 start-page: 7 year: 2016 ident: 1313_CR27 publication-title: Nat Commun – volume: 82 start-page: 2156 issue: 11 year: 2022 ident: 1313_CR42 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-21-2076 – volume: 88 start-page: 31 year: 2018 ident: 1313_CR3 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2017.10.030 – volume: 21 start-page: 284 issue: 5 year: 2020 ident: 1313_CR11 publication-title: Nat Rev Mol Cell Biol doi: 10.1038/s41580-020-0218-z – volume: 36 start-page: 109412 issue: 3 year: 2021 ident: 1313_CR29 publication-title: Cell Rep doi: 10.1016/j.celrep.2021.109412 – volume: 08 start-page: 506095 issue: 31 year: 2022 ident: 1313_CR52 publication-title: bioRxiv doi: 10.1101/2022.08.31.506095 – volume: 22 start-page: 151 issue: 3 year: 2018 ident: 1313_CR4 publication-title: Contemp Oncol – volume: 20 start-page: 326 issue: 3 year: 2019 ident: 1313_CR51 publication-title: Nat Immunol doi: 10.1038/s41590-019-0312-6 – volume: 14 start-page: e0215381 issue: 4 year: 2019 ident: 1313_CR19 publication-title: PLoS One. doi: 10.1371/journal.pone.0215381 – volume: 76 start-page: 6118 issue: 20 year: 2016 ident: 1313_CR22 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-16-1272 – volume: 102 start-page: 18538 issue: 51 year: 2005 ident: 1313_CR30 publication-title: Proc Natl Acad Sci doi: 10.1073/pnas.0509182102 – volume: 111 start-page: 1124 issue: 4 year: 2020 ident: 1313_CR37 publication-title: Cancer Sci doi: 10.1111/cas.14349 – volume: 21 start-page: 7730 issue: 50 year: 2002 ident: 1313_CR46 publication-title: Oncogene doi: 10.1038/sj.onc.1205971 – volume: 20 start-page: 9 year: 2018 ident: 1313_CR33 publication-title: Front Immunol – volume: 6 start-page: 1152 year: 2023 ident: 1313_CR23 publication-title: Commun Biol. doi: 10.1038/s42003-023-05529-z – volume: 13 start-page: 8 year: 2017 ident: 1313_CR39 publication-title: Front Immunol – volume: 39 start-page: 110632 issue: 2 year: 2022 ident: 1313_CR35 publication-title: Cell Rep doi: 10.1016/j.celrep.2022.110632 – volume: 3 start-page: 23 year: 2012 ident: 1313_CR48 publication-title: Front Immunol. doi: 10.3389/fimmu.2012.00023 – volume: 7 start-page: e1424672 issue: 5 year: 2018 ident: 1313_CR32 publication-title: Oncoimmunology doi: 10.1080/2162402X.2018.1424672 – volume: 34 start-page: 3460 issue: 28 year: 2016 ident: 1313_CR5 publication-title: J Clin Oncol doi: 10.1200/JCO.2016.68.6907 – volume: 13 start-page: 244 issue: 1 year: 2014 ident: 1313_CR38 publication-title: Mol Cancer doi: 10.1186/1476-4598-13-244 – volume: 23 start-page: 3711 issue: 14 year: 2017 ident: 1313_CR28 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-16-3215 – volume: 2 start-page: 417 issue: 6 year: 2022 ident: 1313_CR54 publication-title: Cancer Res Commun doi: 10.1158/2767-9764.CRC-22-0017 – volume: 603 start-page: 145 issue: 7899 year: 2022 ident: 1313_CR53 publication-title: Nature doi: 10.1038/s41586-022-04421-w – volume: 38 start-page: 3528 year: 2020 ident: 1313_CR8 publication-title: J Clin Oncol doi: 10.1200/JCO.20.00799 – volume: 379 start-page: 2495 issue: 26 year: 2018 ident: 1313_CR7 publication-title: N Engl J Med doi: 10.1056/NEJMoa1810858 – volume: 6 start-page: e1249561 issue: 1 year: 2017 ident: 1313_CR49 publication-title: Oncoimmunology doi: 10.1080/2162402X.2016.1249561 – volume: 7 start-page: 10501 issue: 1 year: 2016 ident: 1313_CR50 publication-title: Nat Commun doi: 10.1038/ncomms10501 – volume: 10 start-page: 566 issue: 5 year: 2014 ident: 1313_CR47 publication-title: Int J Biol Sci doi: 10.7150/ijbs.8579 – volume: 34 start-page: 302 issue: 5–6 year: 2020 ident: 1313_CR15 publication-title: Genes Dev doi: 10.1101/gad.334433.119 – volume: 7 start-page: a016600 issue: 4 year: 2015 ident: 1313_CR12 publication-title: Cold Spring Harb Perspect Biol doi: 10.1101/cshperspect.a016600 – volume: 38 start-page: 3528 issue: 30 year: 2020 ident: 1313_CR16 publication-title: J Clin Oncol doi: 10.1200/JCO.20.00799 – volume: 178 start-page: 7097 issue: 11 year: 2007 ident: 1313_CR25 publication-title: J Immunol doi: 10.4049/jimmunol.178.11.7097 – volume: 154 start-page: 33 year: 2019 ident: 1313_CR41 publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2019.04.078 – volume: 317 start-page: 2402 issue: 23 year: 2017 ident: 1313_CR17 publication-title: JAMA doi: 10.1001/jama.2017.7112 – volume: 63 start-page: 6501 issue: 19 year: 2003 ident: 1313_CR44 publication-title: Cancer Res
SSID	ssj0062843
Score	2.3456056
Snippet	Clinical trials are currently exploring combinations of PARP inhibitors and immunotherapies for the treatment of ovarian cancer, but their effects on the... Abstract Clinical trials are currently exploring combinations of PARP inhibitors and immunotherapies for the treatment of ovarian cancer, but their effects on...
SourceID	doaj pubmedcentral proquest gale pubmed crossref springer
SourceType	Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	231
SubjectTerms	Analysis Angiogenesis Animals B7-H1 Antigen - genetics BRCA mutations BRCA1 protein BRCA1 Protein - genetics BRCA2 protein BRCA2 Protein - genetics Breast cancer Cancer Cancer therapies Care and treatment Cell death Clinical trials DNA damage DNA repair Female Genes, BRCA2 Genomes Gynecology Humans Immune checkpoint inhibitors Immunomodulation Immunotherapy Inflammation Medical prognosis Medicine Medicine & Public Health Mice Monoclonal antibodies Mutation Ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - genetics Ovarian Neoplasms - metabolism PARP inhibitors PD-L1 protein Poly(ADP-ribose) Polymerase Inhibitors - pharmacology Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use Reproductive Medicine RNA Survival Tumor microenvironment Tumor Microenvironment - genetics Tumors
SummonAdditionalLinks	– databaseName: Publicly Available Content Database dbid: PIMPY link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZgy4ELr_LYUsBICA4QbRzn4ZzQtqICCaoVAlROluNHqdQm7SZbqT3x05lxHm2K6Inbaj152Bl_M5PMfEPIK2uFLtBzCxOrIUApOBYrYz9iK4TWsct9H7Ifn7PdXbG3ly-68ui6S6vsMdEDdcv2jHnbAMIzU2l8Yz6LcrBNYPpY_v74JMAeUvittWuocZOsIfFWOCFri09fFj97ZE4BinlfOCPSWQ34HYsArFaArDM8OB8ZJ8_h_zdSXzJVV9Mor3xL9SZq5-7_ndw9cqdzVem81a375IYtH5D1eQlh-tEZfU198qh_K79Ofm993Z4zqkpD8VdEjUVqCrgebVZHcCbqW-7UdN_TXDeWGgSXUje0OoVwXZWDHGYIXi6_8yft-7gAHh3SZZvXa2vaVLQtIDt7SL7vfPi2_THomjsEGpyiJoi8MoD_w6NEZYobiJtcoVzMU8dtCDqiABoS6zKDlG6FiQzEWlo45cBFUiF_RCZlVdonhKZaxSbUIdjjJC6SLM8st8KGJrNxwXI3Jax_qlJ3zOfYgONQ-ghIpLLVBAmaIL0myPMpeTscc9zyflwrvYXKMkgiZ7f_o1ruyw4CpI2z1MCO0Uhh52CDgCdqI-5UxFzqGNzmC1Q12RbADsgj5-ChgxsNruGUvPESiD0wAa26EgpYBmTxGklujiQBM_R4uNdD2WFWLS_UbkpeDsN4JObhlbZagYzIEwiYWQineNxq_zBpDs4OXABGxGhfjFZlPFIe_PKM5ixMQQ8EXPhdv4Uu7uvfy75x_TSektsRbm7GgkhskkmzXNln5JY-bQ7q5fMOHP4AKXd06Q priority: 102 providerName: ProQuest – databaseName: Springer Journals dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jb9UwELagIMSFpWV5UMBICA4QEcdZnONrRcUBKsRS9WY59rhUavPQS16l9sRPZ8ZZaMoiwe3peZx4mRl_E8_C2DMAZStCbnEGFg2USlKwMtUjBqWsTX0Z6pDtvSt2d9X-fvmhDwprBm_34UoyaOog1ip_3aC2TVWEZ0xEOWJkdHaZXcko2wzZ6J_2Bv2bo8KVQ3jMb_tNjqCQqf9XfXzuQLroLHnhxjQcRDs3_28Kt9iNHnjyeccpt9klqNfZxrxGo_v4lD_nwRU0fGNfZ9fe9zfuG-z71sftueCmdpx-JdwB5ZzAUfJ2dYwP5aGWTsMPQv7qFrgjrVHbli9O0A439UhHrn_n4-rCQ4cCLahojviyc9iFhrcL3kWGnd5hX3befN5-G_VVGyKLaKeNkrDLCGxkkpnCSIcGka-MT2XuJcS4-QZlPgNfOMrVVrnEoRFllTcesY-J5V22Vi9quM94bk3qYhvjQZulVVaUBUhQELsC0kqUfsbEsJHa9inNqbLGkQ6mjcp1t-IaV1yHFddnM_Zy7POtS-jxV-ot4o-RkpJxhz8WywPdy7aGtMgdioKl3HQeOR8hJiTSm0T43Asc5hPiLt1Fto4qRc8ReiM-Rsw3Yy8CBSkVnIA1fWwELgOl55pQbk4oURnYafPAwbpXRo1OSgRyiBNFOWNPx2bqSQ52NSxWSKPKDC1hEeMj7nUMP05aIorBF2CLmojCZFWmLfXh15CqXMQ58oHCF78aJOLnuP687A_-jfwhu56QUAkRJWqTrbXLFTxiV-1Je9gsHwft8AMKamIR priority: 102 providerName: Springer Nature
Title	BRCA1 and BRCA2 deficient tumour models generate distinct ovarian tumour microenvironments and differential responses to therapy
URI	https://link.springer.com/article/10.1186/s13048-023-01313-z https://www.ncbi.nlm.nih.gov/pubmed/38017453 https://www.proquest.com/docview/2902131719 https://www.proquest.com/docview/2895259103 https://pubmed.ncbi.nlm.nih.gov/PMC10683289 https://doaj.org/article/e476deccc4654fb88441e23fa21f6f1f
Volume	16
WOSCitedRecordID	wos001110487300001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVADU databaseName: BioMedCentral customDbUrl: eissn: 1757-2215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0062843 issn: 1757-2215 databaseCode: RBZ dateStart: 20080101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1757-2215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0062843 issn: 1757-2215 databaseCode: DOA dateStart: 20080101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1757-2215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0062843 issn: 1757-2215 databaseCode: M~E dateStart: 20080101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1757-2215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0062843 issn: 1757-2215 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1757-2215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0062843 issn: 1757-2215 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1757-2215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0062843 issn: 1757-2215 databaseCode: PIMPY dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: Springer Nature Consortium list (Orbis Cascade Alliance) customDbUrl: eissn: 1757-2215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0062843 issn: 1757-2215 databaseCode: RSV dateStart: 20081201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwELdg8MALAgYsMIqREDxAtDjOh_PYTptAgqoqMJUny3FsmDRS1KaTtif-dO7sJDRDwAsvVRNf4sR3vo_27neEPDdG6BI9tyg1GgKUkmOxMvYjNkJondjC9SE7eZdPp2KxKGZbrb4wJ8zDA_uFOzBJnlUwj0bgLwu3BfttYm5VzGxmmUXtG-VFF0x5HZyB0uVdiYzIDtagqRMRgn0KEV-Gh5cDM-TQ-n_XyVtG6WrC5JV_TZ0xOr5DbrdeJB37p79Lrpn6Htkd1xBBf7ugL6jL63Q_mO-SH5P54ZhRVVcUv8W0MogaAXPQZgOB_4q6bjhr-sUhUDeGVrjva93Q5TlE0qru6TB5b7syzt20a7ECquKMrnzKrVnTZkl9bdfFffLp-Ojj4Zuw7bsQavBXmjB2fALXhMepyhWvIKSxpbIJzyw3EbBPwa5Njc0rRFsrq7iCMEgLqyx4LyriD8hOvazNHqGZVkkV6QhMZZqUaV7khhthoio3SckKGxDWsUHqFpQce2OcSReciEx61klgnXSsk5cBedVf891DcvyVeoLc7SkRTtudACGTrZDJfwlZQJ6ibEhfm9orBTkG5xk8XPDaAvLSUaBagBfQqq1ugGVAgK0B5f6AErazHg538idbdbKWcQGuGHh6rAjIs34Yr8QUudosN0AjihRiWRbBLR56ce1fmoMfAhPAiBgI8mBVhiP16VcHNs6iDORAwMSvO5n_9Vx_XvZH_2PZH5NbMe5ZxsJY7JOdZrUxT8hNfd6crlcjcj1f5O5TjMiNydF0Nh85LQBHs7fvZ5_haP7h5CeLYmEf
linkProvider	Directory of Open Access Journals
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwELbKFoleeBXKQqFG4nGAqHnHOSC0LVRddbtaoYLKyTiOXSq1Sdlki7YnfhG_kRnn0aaI3nrgtlpPHNs7883Meh6EvFCKyQQtNztQEhyUxMNkZexHrBiT0tex6UP2ZRSNx2x_P54skN9NLgyGVTaYaIA6zSX-R77uxqCNQNk58fuTHxZ2jcLb1aaFRsUWO2r-E1y24t3wA_y-L1136-Pe5rZVdxWwJGjj0nLNKkDxem4gIuGlYLDrRGjfC7WnbFicAJ4MlI5SrCWWpG4KRr5kWmjQzcL2YN4bZNEHZrd7ZHEy3J18bbA_BLD3mtQcFq4XoCF8ZoFetLCujWedddSf6RLwty64oAwvB2peuq01SnDrzv92fHfJ7drcpoNKPu6RBZXdJ8uDTJT58Zy-oiYA1twsLJNfG582Bw4VWUrxk0tTheU14FBoOTuGmahpG1TQA1Oqu1Q0RYDMZEnzUwGCnLV0GOV4MYXQTNr0ogFMPaLTKjZZFbTMaZUEN39APl_LWTwkvSzP1CNCQyn81JY22BSBnwRRHClPMWWnkfITJ9Z94jR8w2VdvR2biBxx48WxkFe8xoHXuOE1ftYnb9pnTqraJVdSbyA7tpRYd9x8kU8PeA1jXPlRmILUSyzDp0HIwZpWrqeF6-hQO7DMNWRmXiXxtujJB-BlgCsA5m2fvDYUiJ-wASnqNBA4BqxE1qFc7VAC7snucMPpvMbdgp-zeZ88b4fxSYwlzFQ-AxoWB-D0OzZMsVLJV7tpDww2eAGMsI7kdU6lO5IdfjdV2R07BD5g8OK3jZCer-vfx_746m2skVvbe7sjPhqOd56QJRehxHEsl62SXjmdqafkpjwtD4vpsxqKKPl23eL7BxrrxmU
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Zb9QwELagoIoXjpZjoVAjIXiAqHGcw3ncFlYgyqoqUPXNcnyUSm1S7WYrtU_8dGacg005JMTbaj22Y2dm_E08ByEvrBW6QOQWJlaDgVJwDFbGesRWCK1jl_s6ZAe72XQqDg_zvaUofu_t3l1JNjENmKWprLfOjGtEXKRbc9C8sQjgvAkwXwwPLq-TGzFYMujUtf_5oNPFKShf3oXK_Lbf4DjyWft_1c1Lh9NVx8krt6f-UJrc-f_l3CW3W0BKxw0H3SPXbLlG1sclGOOnF_Ql9S6i_tv7Gln91N7Er5Pv2_s7Y0ZVaSj-iqixmIsC5qT14hQGpb7Gzpwe-bzWtaUGtUmpa1qdg32uyp4OXQKX4-38oF3hFlBAJ3TWOPLaOa0r2kSMXdwnXyfvvuy8D9pqDoEGFFQHkX_7AHh4lKhMcQOGkiuUi3nquA2BKRTogsS6zGAOt8JEBowrLZxygIlUyB-QlbIq7SNCU61iE-oQDuAkLpIszyy3woYms3HBcjcirHupUrepzrHixon0Jo9IZbPjEnZc-h2XlyPyuu9z1iT6-Cv1NvJKT4lJuv0f1exItjIvbZylBkREY846BxIB0NNG3KmIudQxeMxN5DTZRLz2qkaOAZIDbgYsOCKvPAUqG1iAVm3MBGwDpu0aUG4MKEFJ6GFzx82yVVJzGeUA8AA_snxEnvfN2BMd70pbLYBG5AlYyCyEIR42zN8vmgO6gQmgRQzEYrArw5by-JtPYc7CFPhAwMRvOun4-Vx_3vbH_0a-SVb33k7k7ofpxyfkVoTyxVgQiQ2yUs8W9im5qc_r4_nsmVcaPwB9NG3Z
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=BRCA1+and+BRCA2+deficient+tumour+models+generate+distinct+ovarian+tumour+microenvironments+and+differential+responses+to+therapy&rft.jtitle=Journal+of+ovarian+research&rft.au=Farokhi+Boroujeni%2C+Salar&rft.au=Rodriguez%2C+Galaxia&rft.au=Galpin%2C+Kristianne&rft.au=Yakubovich%2C+Edward&rft.date=2023-11-28&rft.issn=1757-2215&rft.eissn=1757-2215&rft.volume=16&rft.issue=1&rft.spage=231&rft_id=info:doi/10.1186%2Fs13048-023-01313-z&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1757-2215&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1757-2215&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1757-2215&client=summon